News

Reader based multiplex lateral flow assays are opening new opportunities for biomarker signatures, structured data capture and algorithmic interpretation. This article explores how candidate markers can be assessed, translated into lateral flow and developed into reliable diagnostic systems with the reader, software, manufacture and regulatory pathway considered from the start.

Rapid antibody screening can help identify stronger antibody candidates earlier in immunoassay development. Fleet supports antibody screening across lateral flow, ELISA, Gyrolab™ and other assay formats, with small-volume screening approaches and in-house bioconjugation capability to support better assay decisions.

This article explores ADA assay platforms for immunogenicity studies, comparing ELISA, ECL, SPR, multiplex assays and Gyrolab to support platform selection and reliable assay performance